HealthcareServices

Central Nervous System Biomarkers Market 2026–2030: Forecasting Business Opportunities Ahead

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the central nervous system biomarkers market from 2026–2035 with trusted insights from The Business Research Company

How much is the Central Nervous System Biomarkers Market valued at in 2026, and what valuation is forecast for 2030?

The central nervous system biomarkers market size has experienced robust expansion in recent times. Projections indicate it will expand from $6.14 billion in 2025 to $6.74 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 9.8%. Historically, this growth can be ascribed to several factors, including the increasing occurrence of neurological disorders, developments in neuroimaging and assay technologies, heightened clinical research endeavors in neurology, a greater need for monitoring disease progression, and the broadening of biomarker validation investigations.

The central nervous system biomarkers market size is forecasted to experience significant expansion in the upcoming years. Its value is expected to climb to $9.92 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.2%. This growth over the forecast period is propelled by factors such as increasing investments in precision neurology, the rising utilization of biomarkers in personalized medicine, a growing adoption of AI-driven biomarker discovery, the expansion of biomarker-guided clinical trials, and increasing regulatory acceptance of biomarker endpoints. Prominent trends for the forecast period encompass the increasing adoption of blood-based CNS biomarkers, a growing use of biomarkers in drug development pipelines, a rising focus on early neurodegenerative disease detection, the expansion of companion diagnostic biomarkers, and enhanced integration of multi-omics data.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12632&type=smp

What Drivers Are Influencing The Growth Of The Central Nervous System Biomarkers Market?

The increasing prevalence of neurological conditions is projected to boost the expansion of the central nervous system biomarker market in the future. Neurological conditions, or disorders, encompass a wide array of ailments impacting the brain, spinal cord, and nerves across the body. These conditions can stem from diverse factors such as genetics, infections, autoimmune reactions, degenerative changes, growths, vascular problems, and physical trauma. Central nervous system (CNS) biomarkers are instrumental in neurological disorders, assisting in clinical diagnosis, predicting disease risk or outlook, evaluating disease progression, and monitoring treatment effectiveness. They are crucial for comprehending these diseases and their potential for intervention. For instance, in April 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, Alzheimer’s disease affected an estimated 6.7 million Americans aged 65 and older. This number is expected to nearly triple to 14 million by 2060. Moreover, the number of people living with the disease doubles every five years after age 65. Consequently, the uptick in neurological illnesses is a significant driver for the growth of the central nervous system biomarker market.

What Segments Are Included Within The Central Nervous System Biomarkers Market?

The central nervous system biomarkers market covered in this report is segmented –

1) By Type: Safety Biomarker, Efficacy Biomarker, Validation Biomarker, Other Types

2) By Disease: Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Traumatic Brain Injury, Other Diseases

3) By Application: Drug Discovery And Development, Personalized Medicines, Disease Risk Assessment, Diagnostics, Other Applications

4) By End-Users: Diagnostic Labs, Clinics, Hospitals, Research Centers, Other End-Users

Subsegments:

1) By Safety Biomarker: Toxicity Biomarkers, Adverse Event Biomarkers

2) By Efficacy Biomarker: Pharmacodynamic Biomarkers, Response Biomarkers

3) By Validation Biomarker: Predictive Biomarkers, Prognostic Biomarkers

4) By Other Types: Diagnostic Biomarkers, Biomarkers For Disease Progression

What Trends Are Reshaping The Dynamics Of The Central Nervous System Biomarkers Market?

Companies operating in the central nervous system biomarker market are primarily focused on introducing next-generation solutions, such as assay kits. An assay kit is defined as a pre-packaged set of reagents and materials utilized for conducting a specific scientific analysis. For instance, in June 2023, Sysmex Corporation, a Japan-based research and development company, unveiled an Automated Immunoassay System. This assay kit is engineered to identify amyloid beta (Aß) accumulation in the brain, a known cause of Alzheimer’s disease, by using only a small amount of blood. The kit accurately measures the ratio of Aß peptides in the blood through its automated immunoassay system. This capability assists clinicians in identifying Aß accumulation in the brain from a small amount of blood, thereby enabling earlier diagnosis and treatment for patients.

Who Are The Prominent Global Companies Shaping The Central Nervous System Biomarkers Market Landscape?

Major companies operating in the central nervous system biomarkers market are F. Hoffmann-La Roche AG, Novartis AG, Siemens Healthineers, Thermo Fisher Scientific Inc, Abbott Laboratories, Merck KGaA, Eurofins Scientific, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Axon Neuroscience SE, Alector Inc., Oryzon Genomics S.A., Banyan Biomarkers Inc., Anavex Life Sciences Corp., Applied Neurosolutions Inc., C2N Diagnostics, Alzheon Inc., DiaGenic ASA, Avid Radiopharmaceuticals Inc., Cassava Sciences Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Central Nervous System Biomarkers Market?

North America was the largest region in the central nervous system biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Central Nervous System Biomarkers Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12632&type=smp

Browse Through More Reports Similar to the Global Central Nervous System Biomarkers Market 2026, By The Business Research Company

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Neurological Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795